Related Experiment Videos
Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia.
Ke Lin1, Paul D Sherrington, Michael Dennis
1Department of Haematology, Royal Liverpool University Hospital, United Kingdom.
Blood
|August 1, 2002
Summary
In chronic lymphocytic leukemia (CLL), p53 dysfunction and CD38 expression are key adverse prognostic factors. These markers help explain poor outcomes in patients with low IgV(H) mutation levels.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Established adverse prognostic factors for chronic lymphocytic leukemia (CLL) include CD38 expression, IgV(H) mutation status, and TP53 gene defects.
- p53 pathway disruption can occur via mechanisms beyond TP53 mutation.
- A novel screening test identifies p53 dysfunction from mutations in p53 or ATM genes.
Purpose of the Study:
- To evaluate the predictive value of a new p53 dysfunction screening test.
- To determine the relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in CLL.
Main Methods:
- Examined IgV(H) mutation, CD38 expression, and p53 dysfunction in CLL cells from 71 patients.
- Assessed p53 dysfunction via impaired p53/p21 response to ionizing radiation.
- Analyzed survival data from 69 patients based on these parameters.
Main Results:
- Lack of IgV(H) mutation (<5%), CD38 positivity (>20%), and p53 dysfunction were independently confirmed as adverse prognostic factors.
- Nearly all p53-dysfunctional and CD38-positive patients exhibited low IgV(H) mutation (<5%).
- Patients with p53 dysfunction and/or CD38 positivity accounted for the poor survival in the low IgV(H) mutation group.
Conclusions:
- Poor outcomes in CLL patients with low IgV(H) mutation may be linked to a higher prevalence of p53 dysfunction and/or CD38 positivity.
- CLL patients with CD38 negativity and intact p53 function may experience prolonged survival irrespective of IgV(H) mutation status.